Gilead Sciences Profile

72.44
USD 0.03  0.0414%
71.16Last Month High 77.07 
72.12Trading Day  High 72.62 

Bona fide gift to James Meyers of 1327 shares of Gilead Sciences subject to Section 16

Gilead Sciences Inc insider trading alert for gift of common stock by James Meyers, EVP Worldwide Commercial Ops, on November 13, 2017. This event was filed by Gilead Sciences Inc with SEC on 2017-11-13. Statement of changes in beneficial ownership - SEC Form 4. James Meyers is currently serves as executive vice president - worldwide commercial operations of Gilead Sciences Inc [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences Inc (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 8,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 94.63 B. Gilead Sciences Inc conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 1.31 B outstanding shares of which 16.84 M shares are currently shorted by private and institutional investors with about 2.17 trading days to cover. GILEAD SCIENCES currently holds about 21.61 B in cash with 14.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Gilead Sciences Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gilead Sciences Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
< 1% 
Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGilead Sciences Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address333 Lakeside Drive, Foster City, CA 94404, United States
Foreign Associates
ExchangeNASDAQ
CIK Number00882095.0
ISINUS3755581036
CUSIP375558103
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.gilead.com
Contact Number650 574 3000
CurrencyUSD - US Dollar

Recommendations

Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
93.29Buy14Odds
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Gilead Sciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate2.15April 27, 2017
Gilead Sciences Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate